Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genentech’s Alecensa Joins The ALK Inhibitor Market

This article was originally published in The Pink Sheet Daily

Executive Summary

Alectinib will launch within two weeks for second-line ALK-positive non-small lung cancer at the price of $12,500 per month.

You may also be interested in...



Roche: Slow And Steady Wins The Race

The firm got off to a solid start in 2016, which should see its biggest launches in years, but its core strength remains executing long-term management of its key franchises.

Pfizer Expands Xalkori Labeling To New, Rare Lung Cancer Subtype

New indication now allows use in non-small cell lung cancer patients with rare ROS-1 genetic alterations.

Novartis’ Zykadia Sets New “Breakthrough” Speed Record For NME Review

FDA grants accelerated approval to ceritinib following a four-month review. The ALK inhibitor is indicated for non-small cell lung cancer patients who have progressed on or are intolerant of Pfizer’s Xalkori.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM010563

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel